Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer

Table 4 Real-world studies of second-line therapy following failure of Folfirinox[36-44]

Ref.	n	M1	2L regimen	mPFS in mo	mOS in mo	Remarks	AE
Portal et al[36], 2015	57	100%	GnP	5.1	8.8	Prospective cohort	38% grade 3-4 toxicity
Mita et al[37], 2019	30	80%	GnP	3.8	7.6	Phase II	70% grade 3-4 toxicity
Tsang et al[38], 2019	159	67%	GnP 78; Gem 81	-	5.8; 4.6	Population-based, three Canadian provinces	-
Zhang et al[39], 2018	60	73%; 75%; 73%	GnP 30; Gem 8; BSC 22	3.6; 2.5	5.7; 3.8	Single center	More grade 3-4 fatigue in Gem
Nguyen et al[40], 2017	30	77%	GnP	3.7	12.4	Single center	Grade 3-4 thrombocytopenia (33%), anemia (23%), nausea (17%)
Bertocchi et al[41], 2015	23	100%	GnP	3.0	5.0	Single center	-
Zhang et al[42], 2015	28	82%	GnP	3.0	5.7	Single center	Grade 3-4, anemia (25%), thrombocytopenia (25%), neutropenia (18%)
Caparello et al[44], 2016	71	-	GnP	2.5	6.2	Single center	-
Rissy et al[43], 2017	12	100%	GnP	4.9	-	Single-center	No grade 3-4 toxicity reported

BSC: Best supportive care; Gem: Gemcitabine; GnP: Gemcitabine/Nab-paclitaxel; M1: metastatic disease; mOS: Median overall survival; mPFS: Median progression-free survival.